Resumen

CARRION-MADRONAL, IM; SANCHEZ-DEL MORAL, R  y  VILLALBA-MORENO, AM. Dalbavancin as prolonged-salvage treatment in prosthetic joint infection. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.4, pp.423-424.  Epub 19-Sep-2022. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x20210004000016.

Dalbavancin is an antibacterial agent that belongs to the group of semisynthetic lipoglicopeptides of long half-life, with great activity in grampositive microorganisms and with an acceptable adverse effects profile. To date, it has been authorized for the treatment of skin and soft tissue infections in adults, with no indication ofbone and joint infections.

Most cases of joint prosthetic infection described in the literature with dalbavancin in prolonged treatment have been for a period not exceeding 4 weeks. A series of cases of prosthetic joint infection treated for a long time and as salvage with dalbavancin are described

Palabras clave : Dalbavancin; methicillin-resistant Staphylococcus; prolonged treatment; prosthetic joint infection.

        · resumen en Español     · texto en Español     · Español ( pdf )